Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Male or female patients aged over 18 years
* Affiliated with the French social security system
* Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR \< 30 mL/min/1.73 m², or GFR \< 45 mL/min/1.73 m² with albuminuria \> 30 mg/g, or GFR \< 60 mL/min/1.73 m² with albuminuria \> 300 mg/g)
* Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment
* Having expressed no objection to participation in this study
Exclusion Criteria:
* Legally protected adult (Article L1121-8 of the French Public Health Code)
* Person deprived of liberty (Article L1121-8 of the French Public Health Code)
* Pregnant woman
* Patient who has undergone a normal coronary exploration within the past year
Primary outcome measure(s)
To assess the prognostic value of impaired coronary flow reserve measured by CZT myocardial perfusion imaging — 2-year follow-up Composite endpoint including cardiac mortality, non-fatal myocardial infarction, non-fatal ischemic stroke, and hospitalization for heart failure.
Trial sites (1)
Facility
City
Region
Status
CHU Grenoble Alpes
La Tronche
France
More University Hospital, Grenoble trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
